UNSPSC 51383311: Diclofenac diethylamine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11CL2NO2.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TGQ35Z71K. European Medicines Agency schedules diclofenac diethylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01669MIG. The term diclofenac diethylamine is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule diclofenac diethylamine under HS 29224995 and SITC 51465.

As of Q4 2014, DICLOFENAC DIETHYLAMINE remains US FDA's Preferred Term for this commodity. Diclofenac diethylamine bears US NLM identifiers UMLS ID C0771369 and NCI Concept Code C87322. SMILES: CCNCC.C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.

UNSPSC 51383311 Diclofenac diethylamine (Commodity) does not align with the recent state and local procurement activity tagged under this code. The single opportunity in the most-recent-opportunities block—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—involves opioid-reversal medications and drug disposal systems, not diclofenac diethylamine, a topical nonsteroidal anti-inflammatory drug formulation. The mismatch suggests either a cataloging error in the source data or inconsistent code assignment by the issuing body.

The Seminole County procurement, posted June 30, 2026 with a response deadline of July 26, 2023, seeks annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the county community health building in Sanford, Florida. The solicitation is an IFB with standard state and local compliance requirements—drug-free workplace certification, E-Verify compliance, workers' compensation and liability insurance—and potential FEMA funding. The contract awards on a fixed-fee basis with a two-year initial term and one-year renewal option. No specific set-aside designations are noted. The code shows little relevant recent activity under its nominal pharmaceutical scope.